Contact us

Your role*
- Medical professional
- Investor
- Media
- Strategic partner
- Other
First Name*
First
Last Name*
Last
Contact Email*
Country
Country
Topic
Topic
Topic
Topic
Message*
*
I agree to receive an email or phone response from Immunicom to my inquiry. The information submitted will be governed by Immunicom’s Privacy Policy.*
*
I am 18-years of age or older*
CAPTCHA
Email
This field is for validation purposes and should be left unchanged.

Additional Contact Information

CORPORATE HEADQUARTERS
MAILING ADDRESS

Immunicom, Inc.

6048 Cornerstone Ct W
Suite D
San Diego, CA 92121

PHONE

General Inquiries

(657) 202-6388

Media Relations

(657) 202-6040

EMAIL

General Inquiries

business@immunicom.com

Public Relations

publicrelations@immunicom.com

Immunicom Inc.

HEADQUARTERS

San Diego, CA

RESOURCES

Terms of Use

Privacy Policy

FCOI Policy

Instructions for Use

GET IN TOUCH

Contact us

Newsletter Subscription

Immunicom’s Immunopheresis® therapy, including the LW-02 blood-filtering immunotherapy device, has not been approved by the US Food and Drug Administration and is an investigational therapy in all of Immunicom’s ongoing clinical research studies. Immunicom’s LW-02 blood-filtering immunotherapy device has been granted European CE Mark Certification for use in adults with advanced, refractory, triple-negative breast cancer in Europe.

Contact us

Additional Contact Information

CORPORATE HEADQUARTERSMAILING ADDRESS

PHONE

EMAIL

Immunicom Inc.

HEADQUARTERS

San Diego, CA

RESOURCES

GET IN TOUCH

Your choices regarding cookies on this site

Essential Cookies

Functional Cookies

Marketing and Analytics Cookies

CORPORATE HEADQUARTERS
MAILING ADDRESS